This is spot on CTPA is the gold standard for pulmonary embolism diagnosis. Technegas is used for VQ exams when a patient can't undergo a CTPA, the 5 main reasons being they are pregnant, they are young (under 30), they have a contrast allergy, they have kidney disease or they have hyperthyroidism. I don't have stats to back this up but it's maybe 5-10% of PE patients Technegas is not competing with CTPA, it is competing with the alternative venting agent they use for VQ exams in the US called DTPA. They stopped using DTPA in Australia about 15 years ago because it gives terrible quality images. if people are holding out hope that technegas will replace CTPA they fundamentally misunderstand what technegas's intended us is. For technegas to replace CTPA it would mean US doctors are not following best practice.
CYC Price at posting:
$1.98 Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)